Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parathyroid hormone oral - Unigene

Drug Profile

Parathyroid hormone oral - Unigene

Alternative Names: 768974; GSK 768974; PTH 1-31; PTH 131A; PTH oral - Unigene

Latest Information Update: 12 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unigene Laboratories
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones; Recombinant proteins
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 02 Jul 2013 Discontinued - Phase-II for Postmenopausal osteoporosis in USA (PO)
  • 08 Mar 2012 Parathyroid hormone oral - Unigene is available for licensing (\www.unigene.com\)
  • 06 Dec 2011 Unigene terminates exclusive worldwide license agreement with GlaxoSmithKline and regains all rights to its oral parathyroid hormone product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top